WO2000053234A1 - Lipid soluble radioactive metal chelates for tumor therapy - Google Patents

Lipid soluble radioactive metal chelates for tumor therapy Download PDF

Info

Publication number
WO2000053234A1
WO2000053234A1 PCT/US2000/006207 US0006207W WO0053234A1 WO 2000053234 A1 WO2000053234 A1 WO 2000053234A1 US 0006207 W US0006207 W US 0006207W WO 0053234 A1 WO0053234 A1 WO 0053234A1
Authority
WO
WIPO (PCT)
Prior art keywords
indium
radioactive metal
lipid soluble
metal chelate
tumor
Prior art date
Application number
PCT/US2000/006207
Other languages
French (fr)
Inventor
Madhukar Thakur (Mathew) L.
Original Assignee
Thomas Jefferson University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thomas Jefferson University filed Critical Thomas Jefferson University
Priority to CA002366593A priority Critical patent/CA2366593A1/en
Priority to JP2000603723A priority patent/JP2002538225A/en
Priority to EP00921373A priority patent/EP1165146A4/en
Publication of WO2000053234A1 publication Critical patent/WO2000053234A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • the present invention generally relates to the field of oncology and a method of injecting radionuclides for tumor therapy, and more particularly to the use of a class of lipid soluble radioactive metal chelate compounds for treatment of malignant, benign, or inoperable tumors.
  • Intratumoral injection of certain radionuclides for therapy is drawing increasing attention.
  • Investigators have begun to use intratumoral therapy, especially where tumors are inoperable or where incision of tumors is associated with high risks to the patient.
  • Radionuclide therapy is particularly useful for treating a variety of tumors, including inoperable tumors; prostate tumors, for example, which are confined but are associated with high risk following surgical intervention; and brain tumors such as glioma.
  • radioactive metal chelates in general, and Indium-I l l lipid soluble complexes, in particular, is based upon work with such agents in the diagnostic imaging field, especially for labelling cellular blood elements.
  • two of the lipid soluble chelates of IndiumJ l l have been prepared previously. These compunds are Indium-l l l-oxine (8-hydroxyquinoline; see ML Thakur, RE Coleman, and MJ Welch.
  • Indium-l l l-oxine has a higher thermodynamic stability and is smaller in size than Indium-l l l-oxine. These differences result in the more efficient labeling of cells under physiologic conditions by Indium-l l l-Merc. Whereas Indium-l l l-Merc can label cells in the presence of plasma, Indium-l l l-oxine cannot efficiently label cells unless such cells are suspended in balanced salt solutions, such as isotonic saline.
  • Indium-I l l also decays by the emission of two ⁇ -rays of 173 Kev (89%) and 247 Kev (94%). These two ⁇ -rays are useful for scintigraphic imaging.
  • the present invention takes advantage of the lipid soluble nature of Indium- 111 complexes, along with the radioactive properties of these complexes, and utilizes the radioactive metal chelate as a means of treating tumors.
  • the present invention is distinct from receptor-specific agents, such as radiolabeled antibodies or radiolabeled peptides and is distinct from metabolic agents, such as radiodeoxyuridine.
  • IndiumJ l l is one example of an appropriate radioactive metal chelate for tumor therapy
  • other lipid soluble radioactive chelate could be used, so long as such compounds bind tightly to cell cytoplasmic components.
  • Such alternative lipid soluble compounds include Indium-l l l-tropolone (2-hydroxy-2,4,6- cylcoheptatrienone), Rhenium- 186 or Rhenium- 188 chelated with sesta-MIBI (methoxy isobutyl isonitrile), HMPAO, or tetrofosnine. (Holman BL, Jones AG, Lister-James J. et al.
  • radioactive metal chelates could be directed against a variety of other tumors, including hepatoma, melanoma, breast cancer, pancreatic cancer, lung cancer, sarcomas, and carcinoids.
  • Known metastatic tumors can also be treated similarly.
  • the success of the agent used depends upon its homogeneous distribution into the tumor mass. Such a homogeneous distribution is dependent upon the skill and judgment of a physician injecting the agent. As is customary with many therapeutic agents, repeated injections of the agent may be necessary, depending upon the individual patient and the size, location, and type of tumor targeted for therapy.
  • lmCi of Indium-I l l injected into a 1 cc tumor 1.3 X 10 13 atom and 10 9 cells
  • the emission of gamma rays by such radioactive metal chelates may lead to delivery of some radiation to normal organs and tissue within vicinity of the targeted tumor.
  • Such expected radiation dose the normal organs and tissue will have to be determined prior to administration of the therapeutic dose.
  • To arrest tumor cell proliferation means to inhibit cell proliferation, to slow the rate of cell proliferation, to arrest cell proliferation, or to kill tumor cells.
  • the present invention is a method of injecting a class of lipid soluble radioactive metal chelate compounds for intratumoral treatment of malignant, benign, metastatic, or inoperable tumors.
  • the present invention also involves a multisquirter device used to inject the lipid soluble radioactive metal chelate compounds for intratumoral treatment, where the device is designed such that a compound injected with said needle is distributed radially in a uniform volume.
  • FIG. 1 A polaroid picture of two mice bearing human colorectal cancer (LS174T). The mouse on the right received Indium-l l l-oxine (648 ⁇ Ci) 22 days previously, and the mouse on the left (control) received only placebo. Excessive tumor growth in the control animal is visible.
  • Figure 3 A schematic drawing of a needle that will permit more homogeneous distribution of radioactivity in the tumor than using a conventional, single, open-ended needle.
  • the end of the needle in question is sharp for penetration but is blocked.
  • the part of the needle has microholes on its surface that will cause a "spray" of the radiaoctive agent, thereby resulting in more homogeneous distribution of the radioactive solution.
  • mice Four athymic nude mice weighing between 15-18 g were injected intramuscularly in the right flank with approximately 5xl0 6 viable human colorectal carcinoma cells LS174T, human prostate tumor DU145 (male mice), or human breast tumor T74D (female mice). Tumors were allowed to grow to approximately 0.5 cm in diameter.
  • Indium- 111 -oxine is available commercially (Amersham Int. , Arlington Heights, IL). For this procedure, however, Indium-l l l-oxine was prepared by using a procedure published previously (Thakur ML et al, J Lab Clin Med 89: 217-228, 1977). Indium-I l l in chloride form was obtained from MDS Nordion, Vancouver, Canada. Briefly, to the 10 ⁇ l Indium-111-Ch Solution (1 mCi, 0.05 N HC1), 1 ml of 0.3 M acetate buffer pH-5.4 was added, followed by 50-100 ⁇ g 8-hydroxyquinoline in 50 ⁇ l ethanol.
  • reaction mixture was then extracted twice with 1 ml chloroform or methylene chloride.
  • the organic layer was separated each time and combined. Greater than 95 % of the activity was extracted.
  • Organic solvent was evaporated, and the residue was taken up in 100 ⁇ l ethanol. which was then diluted to 400 ⁇ l with 0.9% NaCl.
  • the agent was prepared as follows. To one mCi Indium-I l l -chloride solution in 10 ⁇ l (0.05 M HC1), 150 ⁇ l of 0.05 M phosphate buffer (pH-7.4) was added followed by 50 ⁇ g of Merc in 50 ⁇ l phosphate buffer pH-7.4. This reaction mixture was not extracted in CHCh and used as such. Alternatively the resultant complex could also be extracted in chloroform or methylene chloride and be subsequently treated as in the preparation of Indium- 11 1-oxine.
  • Injecting agents On day one, two of the four tumor-bearmg mice received a single intratumoral injection of approximately 100 ⁇ l Indium-l l l-oxme Mice were placed in an lonization chamber, and radioactivity was recorded after the injection and then daily for 28 days On each day, radioactivity was corrected for decay, and the percent of injected dose retained in the animal was calculated and recorded. Animals were also weighed daily in a calibrated balance.
  • mice On day one, all four mice were lightly anesthetized and photographs taken. Mice receiving Indium-l l l-oxine were also imaged with a gamma camera 28 days later. This qualitatively recorded the distribution of radioactivity, 28 days after it was injected.
  • the control animals received a single intratumoral injection of 100 ⁇ l of 25% ethanol m 0.9% NaCl Two radioactive animals and the control animals were then cared for m two separated cages and allowed to eat and drink at liberty.
  • mice treated with Indium-l l l-oxine received 100 ⁇ l of Indium-l l l-Merc each in two places in tumors
  • the control animals also received two intratumoral injection of 0.05 M phosphate buffer pH-7.4.
  • mice were weighed daily and radioactivity remaining in their bodies was measured for an additional 10 days
  • Fig. 1 is a photograph of two mice, one receiving Indium-l l l-oxine (right) and
  • the tumor in the control mouse at right has grown substantially larger (3.2 cm), but the one m the treated animal has not grown Results were similar in the remaining two mice.
  • Fig. 2 shows gamma camera image (left) taken on day 22 after Indium-l l l-oxine injection
  • Gamma camera images show that nearly all of the radioactivity was retained in the tumor.
  • Ten days after the injection of Indium-l l l-Merc all of the radioactivity was also retained in each animal body (right). Both mice treated with Indium-I l l agents had neither gained nor lost body weight. The control animals gained 20.4% and 20.5 % body weight.
  • Fig. 3 shows a needle designed for intratumoral injection, which will permit more homogeneous distribution of radioactivity in the tumor than by using a conventional needle.
  • mice Human prostate and human breast tumors were grown in two separate groups of nude mice. Six mice in each group were divided in two subgroups of 3 mice each. Three mice were treated with intratumoral injections of either Indium-l l l-oxine or Indium-l l l-Merc. Each group of mice was then placed in rodent cages separately and cared for with regular diet and water ad lib. Each day the animals were weighed, and tumor diameter was measured three times with a Vernier caliper.
  • Radioactivity received by each animal was carefully measured, and each day the amount of radioactivity retained in the animal body was measured using an energy calibrated radiation dose calibrator.
  • a second dose of the same agent was readministered, also intratumorally and the procedure was followed as described above, for the next two weeks.
  • the animals were sacrificed, and organs such as the liver, spleen, lungs, kidneys, and bladder were harvested together with the tumor. These organs were then weighed. Indium-I l l associated with each tissue was counted, and the radioactivity distributed in each organ was calculated as the percent of the total radioactivity retrained in each animal.
  • Indium- I l l was obtained as a radiochemical in chloride form from MDS Nordion in Canada and converted into Indium-l l l-oxine using the procedure described previously. (Thakur et al, J Lab Clin Med 89: 217-228, 1977). It should be noted that while studies with Indium-l l l-oxine have been done previously to assess cytotoxicity, these preparations of Indium-l l l-oxine were diluted in 0.9% NaCl excessively, stored and used.
  • the organic solvent containing greater than 95 % of the radioactivity was then separated, and the solvent was evaporated with a gentle stream of nitrogen. After a complete evaporation, 50 ⁇ l of ethanol was added followed by 150 ⁇ l of 0.9 % NaCl. Fifty ⁇ l doses were then withdrawn, measured for radioactivity, and administered intratumorally in one or more places. Control animals received a similar volume of 25 % ethanol in 0.9% saline in the tumors. Radioactivity received by each animal was then determined by placing the animal in the radioactivity dose calibrator and then measured daily.
  • Indium-l l l-Merc was prepared also by a method described previously.
  • Human prostate cancer cells DU145 (5x 10 6 ) were implanted in the thigh of nude mice and allowed to grow to less than 0.5 cm in size. These were treated with Indium-l l l-oxine.
  • human breast cancer cells (5 x 10 6 ) T47D were implanted similarly. These were also allowed to grow to up to 0.5 cm in diameter.
  • the average radiation dose with Indium-l l l-oxine received by each animal was estimated to be approximately 131 Gy.
  • the average tumor growth during the treatment period in the treated mice was 117% as compared to 200% in the untreated mice (Fig. 4). On the average, none of the treated or untreated mice either gained or lost body weight. At sacrifice, the tumor retained 86.5% of the injected activity corrected for decay.
  • the kidney uptake was 7.5 % , and the liver 5.4% .
  • the average radiation dose received by animals with Indium-l l l-Merc was estimated to be approximately 127 Gy.
  • the average tumor growth in the treated mice was 172% , as compared to 477% in the untreated control animals (Fig. 5). All animals gained some body weight.
  • the Merc treated tumors had retained 92.97% of the injected activity.
  • the kidney had 4.03 % and the liver 1.02% .
  • Indium- 111 is a cyclotron produced radionuclide that decays by electron capture with a physical half-life of 2.83 d. This decay processes, and the atomic and nuclear transitions that ensue to reach the ground state of u l Cd, result in the emission of two gamma rays (171 keV - 90% and 245 keV - 94%), x-rays, 3-27 keV), conversion electrons (145-171 keV - 9.7% and 219-245 keV - 6.0%), and several Auger electrons (0.5 to 25 keV). Using the techniques and computer code described by Howell et al. (Howell RW,
  • the mean absorbed dose to the tumor is 10-20 times higher than the dose to adjacent healthy tissues or the absorbed dose to the adjacent healthy organs is only 5% - 10% of the dose to the tumor.
  • This radiation dosimetry compares highly favorably to the brachytherapy in which radiation dose to the bladder and rectal wall are 100% to that of the prostate tumor and to that of the external beam therapy in which, on the average, 25 % of the bladder wall and 35 % of the rectal wall receive 100% of the dose to the tumor (Waterman FM, Yue N, Corn BW, Dicker AP. Edema associated with 1-125 or Pd-103 prostate brachytherapy and its impact on post- implant dosimetry: An analysis based on serial CT acquisition. Int J Radiat Oncol Biol Phys 43:447-54, 1999).
  • a multi-squirter (multiple outlet) needle can spray the activity in the entire tumor and can produce even better results.

Abstract

The present invention is a method of injecting a class of lipid soluble radioactive metal chelate compounds for intratumoral treatment of malignant, benign, metastatic, or inoperable tumors.

Description

LIPID SOLUBLE RADIOACTIVE METAL CHELATES FOR TUMOR THERAPY
FIELD OF THE INVENTION
The present invention generally relates to the field of oncology and a method of injecting radionuclides for tumor therapy, and more particularly to the use of a class of lipid soluble radioactive metal chelate compounds for treatment of malignant, benign, or inoperable tumors.
BACKGROUND OF THE INVENTION
Intratumoral injection of certain radionuclides for therapy is drawing increasing attention. (Shyh-Jen Wang, Wan-Yu Lin, Min-Nan Chen, Ching-Shiang Chi, Jung-Ta Chen, William-L Ho, Bor-Tsung Hsieh, Lie-Hang Shen, Zei-Tsan Tsai, Gann Ting, Saed Mirzadeh and Furn F. Knapp, Jr. Intratumoral Injection of Rhenium- 188 Microspheres into an Animal Model of Hepatoma. J Nucl Med 39: 1752-1757, 1998). Investigators have begun to use intratumoral therapy, especially where tumors are inoperable or where incision of tumors is associated with high risks to the patient. Radionuclide therapy is particularly useful for treating a variety of tumors, including inoperable tumors; prostate tumors, for example, which are confined but are associated with high risk following surgical intervention; and brain tumors such as glioma.
The use of radioactive metal chelates, in general, and Indium-I l l lipid soluble complexes, in particular, is based upon work with such agents in the diagnostic imaging field, especially for labelling cellular blood elements. For example, two of the lipid soluble chelates of IndiumJ l l have been prepared previously. These compunds are Indium-l l l-oxine (8-hydroxyquinoline; see ML Thakur, RE Coleman, and MJ Welch. Indium-l l l-labeled leukocytes for the localization of abscesses: preparation, analysis, tissue distribution, and comparison with gallium-67 citrate in dogs. J Lab Gin Med 89: 217-228, 1977) and Indium- H I -Merc (Mercapto pyridine- N-oxide; see Thakur ML, McKenney SL, Park CH. Evaluation of Indium-111-2- mercaptopyridine-N-oxide (Merc) for labeling leukocytes in plasma: A kit preparation. J Nucl Med 26: 518-523, 1982). The lipid soluble nature of these compounds is an important characteristic. When these lipid soluble compounds are placed in the presence of any cell, they are capable of passively diffusing through the cell membrane. As a result, Indium-l l l-oxine has been used to lable blood cells, bacteria, and tumor cells. (Thakur ML, Lavender JP, Arnot RN, Silvester DJ, and Segal AW. Indium-l l l-Labeled Autologous Leukocytes in Man. J Nucl Med 18: 1014-1021, 1977; Thakur ML. Live bacteria labeled with ulIn. Eur J Nucl Med 13:266, 1987; Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, Linehan WM, Robertson CN, Lee RE, Rubin JT, et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. NEJM 316: 889-897, 1987).
A comparison between Indium-l l l-oxine and Indium-l l l-Merc has shown that Indium-l l l-Merc has a higher thermodynamic stability and is smaller in size than Indium-l l l-oxine. These differences result in the more efficient labeling of cells under physiologic conditions by Indium-l l l-Merc. Whereas Indium-l l l-Merc can label cells in the presence of plasma, Indium-l l l-oxine cannot efficiently label cells unless such cells are suspended in balanced salt solutions, such as isotonic saline. In either case, whether in the oxine or Merc form, once Indium-I l l has entered the cells, it firmly binds to cell cytoplasmic components and does not come out of the cells. (See U.S. Patent No. 4,443,426 by Thakur, Madhukar L. ; Thakur, ML and McKenney, SM, Indium 111-mercaptopyridine-N-oxide-labeled human leukocytes and platelets: Mechanism of labeling and intracellular location of mIn and mercaptopyridine N-oxide, J Lab Gin Med. 107: 141-147, 1986; Thakur, ML, Segal, AW, Louis, L, Welch, MJ, Hopkins J, and Peters, TJ, Indium-l l l-Labeled Cellular Blood Components: Mechanism of Labeling and Intracellular Location in Human Neutrophils. J Nucl Med, 18: 1020-1024, 1977; Thakur et al. , J Lab Gin Med, 89: 217-228, 1977). Through the Auger electrons Indium-I l l emits during its decay (tι/2 =67hrs), each atom of Indium-I l l delivers 0J35 rad of radiation dose to a cell lOμ in diameter. The path range of Auger electrons is 8 to 12.5μ. (Silvester, DJ, Consequences of Indium-I l l decay in vivo; calculated absorbed radiation dose to cells labelled by Indium-I l l oxine, J of Labelled Compounds and Radiopharmaceuticals , 13 : 196-197, 1977). Indium-I l l also decays by the emission of two γ-rays of 173 Kev (89%) and 247 Kev (94%). These two γ-rays are useful for scintigraphic imaging.
The present invention takes advantage of the lipid soluble nature of Indium- 111 complexes, along with the radioactive properties of these complexes, and utilizes the radioactive metal chelate as a means of treating tumors. The present invention is distinct from receptor-specific agents, such as radiolabeled antibodies or radiolabeled peptides and is distinct from metabolic agents, such as radiodeoxyuridine. By injecting Indium-l l l-oxine or Indium-l l l-Merc into a tumor, the Indium-I l l atoms enter the tumor cells, bind to tumor cell cytoplasmic components, and deliver high enough radiation dose to the cell DNA such that apoptosis will occur, thereby arresting cell proliferation and/or leading to tumor regression. Chromosomal aberrations in lymphocytes labeled with Indium-I l l have been demonstrated, (ten Berge RJM, Natarajhan, AT, Hardeman MR, et al: Labeling with Indium-I l l has detrimental effects on human lymphocytes: concise communication. J Nucl Med 24:615-620, 1983).
While IndiumJ l l is one example of an appropriate radioactive metal chelate for tumor therapy, other lipid soluble radioactive chelate could be used, so long as such compounds bind tightly to cell cytoplasmic components. Such alternative lipid soluble compounds include Indium-l l l-tropolone (2-hydroxy-2,4,6- cylcoheptatrienone), Rhenium- 186 or Rhenium- 188 chelated with sesta-MIBI (methoxy isobutyl isonitrile), HMPAO, or tetrofosnine. (Holman BL, Jones AG, Lister-James J. et al. A new Tc-99m-labeled myocardial imaging agent, hexakis (t- butylisonitrile) technetium (I) [Tc-99m TBI] : initial experience in the human. J Nucl Med 25: 1350-1355, 1984; Volkert WA, Hoffman TJ, Seger RM, Troutner DE, Holmes RA. 99mTc-propylene amine oxime (99mTc-PnAO); a potential brain radiopharmaceutical. Eur J Nucl Med 9:511-516, 1984; Kelly JD, Forster AM, Higley B, et al. Technetium-99m-tetrofosmin as a new radiopharmaceutical for myocardial perfusion imaging. J Nucl Med 34:222-227, 1993).
In addition to inoperable tumors, certain types of prostate tumors, and brain tumors, such radioactive metal chelates could be directed against a variety of other tumors, including hepatoma, melanoma, breast cancer, pancreatic cancer, lung cancer, sarcomas, and carcinoids. Known metastatic tumors can also be treated similarly. The success of the agent used depends upon its homogeneous distribution into the tumor mass. Such a homogeneous distribution is dependent upon the skill and judgment of a physician injecting the agent. As is customary with many therapeutic agents, repeated injections of the agent may be necessary, depending upon the individual patient and the size, location, and type of tumor targeted for therapy. Typically lmCi of Indium-I l l injected into a 1 cc tumor (1.3 X 1013 atom and 109 cells) will deliver 17.5 Gy/cell where distribution of the compound is uniform.
In the present invention, it is important to note that the emission of gamma rays by such radioactive metal chelates may lead to delivery of some radiation to normal organs and tissue within vicinity of the targeted tumor. Such expected radiation dose the normal organs and tissue will have to be determined prior to administration of the therapeutic dose.
Nonetheless, the results of work with the present invention have shown that the radioactivity remains in the tumor and does not spread in the body (22 days observation time); tumor growth is arrested; and treated mammals did not lose body weight when compared to untreated tumor-bearing mammals of the same species.
DEFINITIONS
To arrest tumor cell proliferation means to inhibit cell proliferation, to slow the rate of cell proliferation, to arrest cell proliferation, or to kill tumor cells. SUMMARY OF THE INVENTION
The present invention is a method of injecting a class of lipid soluble radioactive metal chelate compounds for intratumoral treatment of malignant, benign, metastatic, or inoperable tumors. The present invention also involves a multisquirter device used to inject the lipid soluble radioactive metal chelate compounds for intratumoral treatment, where the device is designed such that a compound injected with said needle is distributed radially in a uniform volume.
Accordingly, it is an object of the present invention to provide a method of treating a tumor in a mammal, comprising administering a therapeutically effective amount of a lipid soluble radioactive metal chelate to a tumor to arrest tumor cell proliferation.
It is another object of the present invention to provide a method of treating a tumor in a mammal, comprising administering a therapeutically effective amount of a lipid soluble radioactive metal chelate intratumorally to arrest tumor cell proliferation, wherein said radioactive metal chelate is one of the group of Indium- l l l-oxine, Indium-l l l-Merc, Indium-l l l-tropolone, Rhenium-186 HMPAO, Rhenium-188 HMPAO, Rhenium-186 sestaMIBI, or Rhenium- 188 sestaMIBI. It is yet another object of the present invention to provide a method of treating a tumor in a mammal, comprising administering a therapeutically effective amount of a lipid soluble radioactive metal chelate intratumorally to arrest tumor cell proliferation, wherein said lipid soluble radioactive metal chelate consists of a radionuclide from one of the group of Indium-114m, Sn-113, Dy-159, Co-56, Fe-59, Cu-67, Y-90, Ru-97, Ru-103, Pd-103, Cd-115, Sn-117, Te-118, Te-123, Ba-131, Ba- 140, Gd-149, Gd-151, Tb-160, Re-186, Re-188, Au-198, or Au-199.
It is another object of the present invention to provide a method of treating a tumor in a mammal, comprising administering a therapeutically effective amount of a lipid soluble radioactive metal chelate intratumorally to arrest tumor cell proliferation, wherein said lipid soluble radioactive metal chelate consists of a chelating agent having a functional group to chelate metal ions with valency states 1 to 7 and said functional group consists of one of the group of OH, NH, NH2, NO2, N3, SH, CO, PO4. CN, NCS, P:Oτ. SCN, S2O3, with donor atoms of C, N, O, P, or S.
It is a further object of the present invention to provide a method of treating a prostate tumor in a mammal, comprising administering a therapeutically effective amount of a lipid soluble radioactive metal chelate to a prostate tumor to arrest prostate tumor cell proliferation.
It is a further object of the present invention to provide a method of treating a prostate tumor in a mammal, comprising administering a therapeutically effective amount of a lipid soluble radioactive metal chelate to said prostate tumor to arrest cell proliferation, where said lipid soluble radioactive metal chelate is Indium-ll l- oxine.
It is another object of the present invention to provide a method of treating a prostate tumor in a mammal, comprising administering a therapeutically effective amount of a lipid soluble radioactive metal chelate to said prostate tumor to arrest cell proliferation, where said lipid soluble radioactive metal chelate is Indium-lll- Merc.
It is another object of the present invention to provide a method of treating an inoperable tumor in a mammal, comprising administering a therapeutically effective amount of a lipid soluble radioactive metal chelate to said inoperable tumor to arrest inoperable tumor cell proliferation.
It is a further object of the present invention to provide a method of treating an inoperable tumor in a mammal, comprising administering a therapeutically effective amount of a lipid soluble radioactive metal chelate to said inoperable tumor to arrest inoperable tumor cell proliferation, where said lipid soluble radioactive metal chelate is Indium-l l l-oxine.
It is another object of the present invention to provide a method of treating an inoperable tumor in a mammal, comprising administering a therapeutically effective amount of a lipid soluble radioactive metal chelate to said inoperable tumor to arrest inoperable tumor cell proliferation, where said lipid soluble radioactive metal chelate is Indium-l l l-Merc.
It is another object of the present invention to provide a method of treating a brain tumor in a mammal, comprising administering a therapeutically effective amount of a lipid soluble radioactive metal chelate to said brain tumor to arrest tumor brain tumor cell proliferation.
It is a further object of the present invention to provide a method of treating a brain tumor in a mammal, comprising administering a therapeutically effective amount of a lipid soluble radioactive metal chelate to said brain tumor to arrest brain tumor cell proliferation, where said lipid soluble radioactive metal chelate is Indium-
111-oxine.
It is another object of the present invention to provide a method of treating a brain tumor in a mammal, comprising administering a therapeutically effective amount of a lipid soluble radioactive metal chelate to said brain tumor to arrest brain tumor cell proliferation, where said lipid soluble radioactive metal chelate is Indium-
111-Merc.
It is another object of the present invention to provide a method of treating a hepatoma in a mammal, comprising administering a therapeutically effective amount of a lipid soluble radioactive metal chelate to said hepatoma to arrest hepatoma cell proliferation.
It is a further object of the present invention to provide a method of treating a hepatoma in a mammal, comprising administering a therapeutically effective amount of a lipid soluble radioactive metal chelate to said hepatoma to arrest hepatoma cell proliferation, where said lipid soluble radioactive metal chelate is Indium-l l l-oxine.
It is another object of the present invention to provide a method of treating a hepatoma in a mammal, comprising administering a therapeutically effective amount of a lipid soluble radioactive metal chelate to said hepatoma to arrest hepatoma cell proliferation, where said lipid soluble radioactive metal chelate is Indium-l l l-Merc. It is another object of the present invention to provide a method of treating a melanoma in a mammal, comprising administering a therapeutically effective amount of a lipid soluble radioactive metal chelate to said melanoma to arrest melanoma cell proliferation.
It is a further object of the present invention to provide a method of treating a melanoma in a mammal, comprising administering a therapeutically effective amount of a lipid soluble radioactive metal chelate to said melanoma to arrest melanoma cell proliferation, where said lipid soluble radioactive metal chelate is Indium-l l l-oxine. It is another object of the present invention to provide a method of treating a melanoma in a mammal, comprising administering a therapeutically effective amount of a lipid soluble radioactive metal chelate to said melanoma to arrest melanoma cell proliferation, where said lipid soluble radioactive metal chelate is Indium-l l l-Merc. It is another object of the present invention to provide a method of treating a metastatic tumor in a mammal, comprising administering a therapeutically effective amount of a lipid soluble radioactive metal chelate to said metastatic tumor to arrest metastatic tumor cell proliferation.
It is a further object of the present invention to provide a method of treating a metastatic tumor in a mammal, comprising administering a therapeutically effective amount of a lipid soluble radioactive metal chelate to said metastatic tumor to arrest metastatic tumor cell proliferation, where said lipid soluble radioactive metal chelate is Indium- 111-oxine.
It is another object of the present invention to provide a method of treating a metastatic tumor in a mammal, comprising administering a therapeutically effective amount of a lipid soluble radioactive metal chelate to said metastatic tumor to arrest metastatic tumor cell proliferation, where said lipid soluble radioactive metal chelate is Indium-l l l-Merc.
BRIEF DESCRIPTION OF THE DRAWINGS
The file of this patent contains at least one drawings executed in color. Copies of this patent with color drawing(s) will e provided by the Patent and Trademark Office upon payment of the necessary fee.
Figure 1. A polaroid picture of two mice bearing human colorectal cancer (LS174T). The mouse on the right received Indium-l l l-oxine (648 μCi) 22 days previously, and the mouse on the left (control) received only placebo. Excessive tumor growth in the control animal is visible. Figure 2. Posterior gamma camera images of two mice which had received
Indium-l l l-oxine 22 days prior (left) and Indium-l l l-Merc 10 days prior (right). Images (white spot on the right) show that a major proportion of the radioactivity is still in the tumor.
Figure 3. A schematic drawing of a needle that will permit more homogeneous distribution of radioactivity in the tumor than using a conventional, single, open-ended needle. The end of the needle in question is sharp for penetration but is blocked. The part of the needle has microholes on its surface that will cause a "spray" of the radiaoctive agent, thereby resulting in more homogeneous distribution of the radioactive solution.
Figure 4. A graph of tumor size versus time for Indium -111-oxine intratumoral injection study on DU145 human prostate cancer tumor-bearing nude mice (n=2) for a period of one month. The tumor growth in treated mice was arrested, whereas the one in the control mammal continued to grow.
Figure 5. A graph of tumor size versus time for Indium-l ll-Merc intratumoral injection study on T47D (human breast cancer) tumor bearing nude mice (n=2) for a period of one month. The tumor growth in treated mice was arrested, whereas the one in the control mammal continued to grow.
DETAILED DESCRIPTION
Results with Indium-I l l were obtained in mammals by using the following methods:
Tumor-bearing mice:
Four athymic nude mice weighing between 15-18 g were injected intramuscularly in the right flank with approximately 5xl06 viable human colorectal carcinoma cells LS174T, human prostate tumor DU145 (male mice), or human breast tumor T74D (female mice). Tumors were allowed to grow to approximately 0.5 cm in diameter.
Preparation of Indium- 111 -oxine : Indium-l l l-oxine is available commercially (Amersham Int. , Arlington Heights, IL). For this procedure, however, Indium-l l l-oxine was prepared by using a procedure published previously (Thakur ML et al, J Lab Clin Med 89: 217-228, 1977). Indium-I l l in chloride form was obtained from MDS Nordion, Vancouver, Canada. Briefly, to the 10 μl Indium-111-Ch Solution (1 mCi, 0.05 N HC1), 1 ml of 0.3 M acetate buffer pH-5.4 was added, followed by 50-100 μg 8-hydroxyquinoline in 50 μl ethanol. The reaction mixture was then extracted twice with 1 ml chloroform or methylene chloride. The organic layer was separated each time and combined. Greater than 95 % of the activity was extracted. Organic solvent was evaporated, and the residue was taken up in 100 μl ethanol. which was then diluted to 400 μl with 0.9% NaCl.
Preparation of Indium- 111 -Merc (2-Mercaptopyridine-N-oxide) :
This was prepared by a method also published previously (Thakur et al J Lab Clin Med 107: 14 1147, 1986; U.S. Patent No. 4,443,426). As stated previously, this agent, because of its higher thermodynamic stability, does not break down in plasma and passively diffuses into cells in the presence of plasma. Indium-l l l-oxine is not capable of binding cells in plasma. However, in solid tumors where plasma protein concentration (particularly transferrin, to which Indium-I l l binds in plasma) is low, both agents should be equally effective.
The agent was prepared as follows. To one mCi Indium-I l l -chloride solution in 10 μl (0.05 M HC1), 150 μl of 0.05 M phosphate buffer (pH-7.4) was added followed by 50 μg of Merc in 50 μl phosphate buffer pH-7.4. This reaction mixture was not extracted in CHCh and used as such. Alternatively the resultant complex could also be extracted in chloroform or methylene chloride and be subsequently treated as in the preparation of Indium- 11 1-oxine.
Injecting agents: On day one, two of the four tumor-bearmg mice received a single intratumoral injection of approximately 100 μl Indium-l l l-oxme Mice were placed in an lonization chamber, and radioactivity was recorded after the injection and then daily for 28 days On each day, radioactivity was corrected for decay, and the percent of injected dose retained in the animal was calculated and recorded. Animals were also weighed daily in a calibrated balance.
On day one, all four mice were lightly anesthetized and photographs taken. Mice receiving Indium-l l l-oxine were also imaged with a gamma camera 28 days later. This qualitatively recorded the distribution of radioactivity, 28 days after it was injected. The control animals received a single intratumoral injection of 100 μl of 25% ethanol m 0.9% NaCl Two radioactive animals and the control animals were then cared for m two separated cages and allowed to eat and drink at liberty.
On day 22, the two mice treated with Indium-l l l-oxine received 100 μl of Indium-l l l-Merc each in two places in tumors The control animals also received two intratumoral injection of 0.05 M phosphate buffer pH-7.4.
As before, the mice were weighed daily and radioactivity remaining in their bodies was measured for an additional 10 days
Results
Fig. 1 is a photograph of two mice, one receiving Indium-l l l-oxine (right) and
Indium-l l l-Merc and one from the control group (left), taken on day 22. As can be seen, the tumor in the control mouse at right has grown substantially larger (3.2 cm), but the one m the treated animal has not grown Results were similar in the remaining two mice.
Fig. 2 shows gamma camera image (left) taken on day 22 after Indium-l l l-oxine injection Gamma camera images show that nearly all of the radioactivity was retained in the tumor. Ten days after the injection of Indium-l l l-Merc, all of the radioactivity was also retained in each animal body (right). Both mice treated with Indium-I l l agents had neither gained nor lost body weight. The control animals gained 20.4% and 20.5 % body weight.
Fig. 3 shows a needle designed for intratumoral injection, which will permit more homogeneous distribution of radioactivity in the tumor than by using a conventional needle.
Additional Studies:
General Procedures
Additional feasibility studies were performed using two lipid soluble agents, Indium-l l l-oxine and Indium-111-Mercaptopyridine-N-oxide (Merc). Human prostate and human breast tumors were grown in two separate groups of nude mice. Six mice in each group were divided in two subgroups of 3 mice each. Three mice were treated with intratumoral injections of either Indium-l l l-oxine or Indium-l l l-Merc. Each group of mice was then placed in rodent cages separately and cared for with regular diet and water ad lib. Each day the animals were weighed, and tumor diameter was measured three times with a Vernier caliper.
Radioactivity received by each animal was carefully measured, and each day the amount of radioactivity retained in the animal body was measured using an energy calibrated radiation dose calibrator. Two weeks after the first injection, a second dose of the same agent was readministered, also intratumorally and the procedure was followed as described above, for the next two weeks. At the end of this period, the animals were sacrificed, and organs such as the liver, spleen, lungs, kidneys, and bladder were harvested together with the tumor. These organs were then weighed. Indium-I l l associated with each tissue was counted, and the radioactivity distributed in each organ was calculated as the percent of the total radioactivity retrained in each animal. Histology on critical organs, such as the liver, bladder, and kidney, as well as tumor histology, was assessed in treated animals and in untreated control animals. Prepa ration of Indium- 111-oxine: Indium- I l l was obtained as a radiochemical in chloride form from MDS Nordion in Canada and converted into Indium-l l l-oxine using the procedure described previously. (Thakur et al, J Lab Clin Med 89: 217-228, 1977). It should be noted that while studies with Indium-l l l-oxine have been done previously to assess cytotoxicity, these preparations of Indium-l l l-oxine were diluted in 0.9% NaCl excessively, stored and used. As a result the compounds obtained in these previous studies were essentially unstable. (See Rao, Sastry, Grimmond, Howell, Govelitz, Lanka and Mylavrapu, Cytotoxicity of Some Indium Radiopharmaceuticals in Mouse Testes, J Nucl Med. (Vol. 29, 1988). Briefly, to one ml of 0.3 M acetate buffer pH-5.6 were added a required quantity of "Jndium-Cb and 50-100 μg oxine (8-hydroxy quinoline) in 100 μl ethanol. The mixture was vortexed and Indium-l l l-oxine thus formed was extracted twice with one ml chloroform or methylene chloride. The organic solvent containing greater than 95 % of the radioactivity was then separated, and the solvent was evaporated with a gentle stream of nitrogen. After a complete evaporation, 50 μl of ethanol was added followed by 150 μl of 0.9 % NaCl. Fifty μl doses were then withdrawn, measured for radioactivity, and administered intratumorally in one or more places. Control animals received a similar volume of 25 % ethanol in 0.9% saline in the tumors. Radioactivity received by each animal was then determined by placing the animal in the radioactivity dose calibrator and then measured daily.
Preparation of Indium- 111 -Merc :
Indium-l l l-Merc was prepared also by a method described previously.
(Thakur et al, J Nucl Med 26: 518-523, 1985). Briefly, to one ml 0.067 M phosphate buffer pH 1.4, a required quantity of Indium- I l l-chloride was added followed by 50 μg Merc in 50 μl 0.067 M phosphate buffer pH 1.4. The reaction mixture was vortexed, and resultant Indium- l l l-Merc was extracted in chloroform or methylene chloride. This was evaporated to dryness, and the complex was taken up in 50 μl ethanol and 150 μl 0.9 % NaCl. A known amount of radioactivity in 50 μl was then injected directly into the tumor in each mouse. The animals were then treated in the manner described previously.
Preparation of tumors:
Human prostate cancer cells DU145 (5x 106) were implanted in the thigh of nude mice and allowed to grow to less than 0.5 cm in size. These were treated with Indium-l l l-oxine.
For treatment with Indium-l l l-Merc, human breast cancer cells (5 x 106) T47D were implanted similarly. These were also allowed to grow to up to 0.5 cm in diameter.
Since the principle of this technique is based on intracellular uptake, the type of tumor used does not matter. Tumor vascularity also does not play a major role in performance.
Results:
The following are the results from each agent.
Indium- 111 -oxine :
The average radiation dose with Indium-l l l-oxine received by each animal was estimated to be approximately 131 Gy. The average tumor growth during the treatment period in the treated mice was 117% as compared to 200% in the untreated mice (Fig. 4). On the average, none of the treated or untreated mice either gained or lost body weight. At sacrifice, the tumor retained 86.5% of the injected activity corrected for decay. The kidney uptake was 7.5 % , and the liver 5.4% .
Indium-lll-Merc:
The average radiation dose received by animals with Indium-l l l-Merc was estimated to be approximately 127 Gy. The average tumor growth in the treated mice was 172% , as compared to 477% in the untreated control animals (Fig. 5). All animals gained some body weight. At sacrifice, the Merc treated tumors had retained 92.97% of the injected activity. The kidney had 4.03 % and the liver 1.02% .
Histologic examinations:
The histologic examination of treated tumor showed considerable necrotic cells whereas the intact cells were visible in the untreated tumor.
Calculations for radiation dosimetrv to tumor and adjacent normal organs
Indium- 111 is a cyclotron produced radionuclide that decays by electron capture with a physical half-life of 2.83 d. This decay processes, and the atomic and nuclear transitions that ensue to reach the ground state of u lCd, result in the emission of two gamma rays (171 keV - 90% and 245 keV - 94%), x-rays, 3-27 keV), conversion electrons (145-171 keV - 9.7% and 219-245 keV - 6.0%), and several Auger electrons (0.5 to 25 keV). Using the techniques and computer code described by Howell et al. (Howell RW,
Rao DV, and Sastry KSR. Macroscopic dosimetry for radioimmunotherapy: Nonuniform activity distributions in solid tumors. Med Phys 16: 66-74, 1989), the mean absorbed dose per unit cumulated activity S is 0.01811 rad/μCi-hr from γ and x-rays (20% of total dose), 0.05776 rad/μCi-hr from conversion electrons (64% of total dose) and 0.01502 rad/μCi-hr from Auger electrons (16% of total dose), making a total of 0.0909 rad/μCi-hr. The cumulated activity A for a 1 mCi intratumoral administration with no biological clearance is 1.44 Ao TP = 1.44 (1000 μCi) (67.9 h) = 9.778 x 104 μCi-hr. Finally, the mean absorbed dose D = A S = 8990 rad per mCi injected. Using the methods described by Howell et al. (Howell et al. Med Phys 16: 66-74,
1989), we have calculated the absorbed dose profile in a spherical 1 gram tumor (diameter = 1.24 cm) after decay of 1 mCi of In-I l l distributed uniformly in the tumor. As indicated above, the mean absorbed dose is 8890 rad per mCi injected. The absorbed dose is somewhat higher at the center of the tumor (9620 rad) and, as expected, drops off to about one-half of that value at the periphery. If it is assumed that the bladder wall is about 0.1 cm from the edge of the tumor, this tissue receives a dose of only about 700 rad. If it is assumed that the rectal wall is 0.3 cm from the edge of the tumor, this tissue only receives a dose of about 400 rad. Therefore the mean absorbed dose to the tumor is 10-20 times higher than the dose to adjacent healthy tissues or the absorbed dose to the adjacent healthy organs is only 5% - 10% of the dose to the tumor. This radiation dosimetry compares highly favorably to the brachytherapy in which radiation dose to the bladder and rectal wall are 100% to that of the prostate tumor and to that of the external beam therapy in which, on the average, 25 % of the bladder wall and 35 % of the rectal wall receive 100% of the dose to the tumor (Waterman FM, Yue N, Corn BW, Dicker AP. Edema associated with 1-125 or Pd-103 prostate brachytherapy and its impact on post- implant dosimetry: An analysis based on serial CT acquisition. Int J Radiat Oncol Biol Phys 43:447-54, 1999).
Unisquirter system versus multisquirter system:
In the present system in which tumors are small, and the needle is unisquirter (single outlet), there may not be truly uniform distribution of the radioactivity throughout the tumor. The tumor cells, which receive the radioactivity, cease to grow, but those which did not continue to multiply, thereby causing the slow but continued tumor growth rather than a complete regression. A multi-squirter (multiple outlet) needle can spray the activity in the entire tumor and can produce even better results.

Claims

I CLAIM:
1. A method of treating a mmor in a mammal, comprising administering a therapeutically effective amount of a lipid soluble radioactive metal chelate intratumorally to arrest tumor cell proliferation.
2. A method of treating a tumor in a mammal, comprising administering a therapeutically effective amount of a lipid soluble radioactive metal chelate intratumorally to arrest tumor cell proliferation, wherein said radioactive metal chelate is one of the group of Indium-l l l-oxine, Indium-l l l-Merc, Indium- 111-tropolone, Rhenium-186 HMPAO, Rhenium-188 HMPAO, Rhenium-186 sestaMIBI, or Rhenium- 188 sestaMIBI.
3. A method of treating a tumor in a mammal, comprising administering a therapeutically effective amount of a lipid soluble radioactive metal chelate intratumorally to arrest tumor cell proliferation, wherein said lipid soluble radioactive metal chelate consists of a radionuclide from one of the group of Indium-114m, Sn- 113, Dy-159, Co-56, Fe-59 Cu-67, Y-90, Ru-97, Ru-103, Pd-103, Cd-115, Sn-117, Te-118, Te-123, Ba-131, Ba-140, Gd-149, Gd-151, Tb-160, Re-186, Re-188, Au- 198, or Au-199.
4. A method of treating a tumor in a mammal, comprising administering a therapeutically effective amount of a lipid soluble radioactive metal chelate intratumorally to arrest tumor cell proliferation, wherein said lipid soluble radioactive metal chelate consists of a chelating agent having a functional group to chelate metal ions with valency states 1 to 7 and said functional group consists of one of the group of OH, NH, NH2, NO2, N3, SH, CO, PO4, CN, NCS, P2O7, SCN, S2O3, with donor atoms of C, N. O, P, or S.
5. A method of treating a prostate tumor in a mammal, comprising administering a therapeutically effective amount of a lipid soluble radioactive metal chelate intratumorally to arrest prostate tumor cell proliferation.
6. The method of Claim 5, where said lipid soluble radioactive metal chelate is Indium-l l l-oxine.
7. The method of Claim 5, where said lipid soluble radioactive metal chelate is Indium- 111 -Merc .
8. A method of treating an inoperable tumor in a mammal, comprising administering a therapeutically effective amount of a lipid soluble radioactive metal chelate intratumorally to arrest inoperable tumor cell proliferation.
9. The method of Claim 8, where said lipid soluble radioactive metal chelate is Indium-l l l-oxine.
10. The method of Claim 8, where said lipid soluble radioactive metal chelate is Indium- 111 -Merc .
11. A method of treating a brain tumor in a mammal, comprising administering a therapeutically effective amount of a lipid soluble radioactive metal chelate intratumorally to arrest brain tumor cell proliferation.
12. The method of Claim 11 , where said lipid soluble radioactive metal chelate is Indium-l l l-oxine.
13. The method of Claim 11, where said lipid soluble radioactive metal chelate is Indium- 111-Merc.
14. A method of treating a hepatoma in a mammal, comprising administering a therapeutically effective amount of a lipid soluble radioactive metal chelate intratumorally to arrest hepatoma cell proliferation.
15. The method of Claim 14, where said lipid soluble radioactive metal chelate is Indium-l l l-oxine.
16. The method of Claim 14, where said lipid soluble radioactive metal chelate is Indium-l l l-Merc.
17. A method of treating a melanoma in a mammal, comprising administering a therapeutically effective amount of a lipid soluble radioactive metal chelate intratumorally to arrest melanoma cell proliferation.
18. The method of Claim 17, where said lipid soluble radioactive metal chelate is Indium-l l l-oxine.
19. The method of Claim 17, where said lipid soluble radioactive metal chelate is Indium-l l l-Merc.
20. A method of treating a metastatic tumor in a mammal, comprising administering a therapeutically effective amount of a lipid soluble radioactive metal chelate to said metastatic tumor to arrest metastatic tumor cell proliferation.
21. The method of Claim 20, where said lipid soluble radioactive metal chelate is Indium-l l l-oxine.
22. The method of Claim 20, where said lipid soluble radioactive metal chelate is Indium-l l l-Merc.
23. A device for intratumoral injection, consisting of a syringe and a needle attached to said syringe, wherein said needle has multiple outlets, such that a compound injected with said needle is distributed radially in a uniform volume.
PCT/US2000/006207 1999-03-09 2000-03-09 Lipid soluble radioactive metal chelates for tumor therapy WO2000053234A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA002366593A CA2366593A1 (en) 1999-03-09 2000-03-09 Lipid soluble radioactive metal chelates for tumor therapy
JP2000603723A JP2002538225A (en) 1999-03-09 2000-03-09 Lipid-soluble radiometal chelates for tumor treatment
EP00921373A EP1165146A4 (en) 1999-03-09 2000-03-09 Lipid soluble radioactive metal chelates for tumor therapy

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12348399P 1999-03-09 1999-03-09
US60/123,483 1999-03-09

Publications (1)

Publication Number Publication Date
WO2000053234A1 true WO2000053234A1 (en) 2000-09-14

Family

ID=22408928

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/006207 WO2000053234A1 (en) 1999-03-09 2000-03-09 Lipid soluble radioactive metal chelates for tumor therapy

Country Status (4)

Country Link
EP (1) EP1165146A4 (en)
JP (1) JP2002538225A (en)
CA (1) CA2366593A1 (en)
WO (1) WO2000053234A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000059550A2 (en) * 1999-04-02 2000-10-12 Ut-Battelle Llc Indium-114m and related compositions applicable in brachytherapie
WO2019243419A1 (en) * 2018-06-19 2019-12-26 Danmarks Tekniske Universitet Brachygel for treatment of cancer and/or for guidance of surgery

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4017596A (en) * 1975-03-03 1977-04-12 Research Corporation Radiopharmaceutical chelates and method of external imaging
US5130118A (en) * 1987-11-06 1992-07-14 Abbott Laboratories Methods and materials for the preparation of metal labelled antibody solutions

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0225409A1 (en) * 1985-12-02 1987-06-16 The Dow Chemical Company Organic amine phosphonic acid complexes for the treatment of calcific tumors
US4925925A (en) * 1988-06-15 1990-05-15 University Of Cincinnati Radioactive rhenium ligated to 2-hydroxy isobutyric acid and method of use
US5192526A (en) * 1989-05-02 1993-03-09 Mallinckrodt Medical, Inc. Kit for preparation of rhenium therapeutic agents for bone cancer without purification
US5460785A (en) * 1989-08-09 1995-10-24 Rhomed Incorporated Direct labeling of antibodies and other protein with metal ions
US5840859A (en) * 1995-07-06 1998-11-24 Research Corporation Technologies, Inc. (Aminostyryl)pyridinium compounds for radiolabelling cell membranes
DE19632052C2 (en) * 1996-08-08 2003-05-28 Michael Eisenhut Benzamide derivatives and their use for the diagnosis and treatment of tumors, in particular melanomas

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4017596A (en) * 1975-03-03 1977-04-12 Research Corporation Radiopharmaceutical chelates and method of external imaging
US5130118A (en) * 1987-11-06 1992-07-14 Abbott Laboratories Methods and materials for the preparation of metal labelled antibody solutions

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HONG, S. S. ET. AL.: "Radiation toxicity of indium-111- 2-mercaptopyridine-N-oxide and HeLa S-3 cells.", THE BRITISH JOURNAL OF RADIOLOGY, vol. 62, May 1989 (1989-05-01), pages 468 - 472, XP002928275 *
See also references of EP1165146A4 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000059550A2 (en) * 1999-04-02 2000-10-12 Ut-Battelle Llc Indium-114m and related compositions applicable in brachytherapie
WO2000059550A3 (en) * 1999-04-02 2001-04-05 Ut Battelle Llc Indium-114m and related compositions applicable in brachytherapie
WO2019243419A1 (en) * 2018-06-19 2019-12-26 Danmarks Tekniske Universitet Brachygel for treatment of cancer and/or for guidance of surgery

Also Published As

Publication number Publication date
CA2366593A1 (en) 2000-09-14
EP1165146A1 (en) 2002-01-02
JP2002538225A (en) 2002-11-12
EP1165146A4 (en) 2003-09-17

Similar Documents

Publication Publication Date Title
ES2268888T3 (en) THE USE OF RADIO-223 TO TALK TO CALCIFIED FABRICS FOR PAIN PAIN AND THERAPY OF CANCER OSEO.
Henriksen et al. Significant antitumor effect from bone-seeking, α-particle-emitting 223Ra demonstrated in an experimental skeletal metastases model
Miao et al. Melanoma therapy via peptide-targeted α-radiation
Imam Advancements in cancer therapy with alpha-emitters: a review
Mulford et al. The promise of targeted α-particle therapy
Miao et al. Peptide-targeted radionuclide therapy for melanoma
Das et al. 170Tm-EDTMP: a potential cost-effective alternative to 89SrCl2 for bone pain palliation
Chan et al. Influence of tumour size on the efficacy of targeted alpha therapy with 213 Bi-[DOTA 0, Tyr 3]-octreotate
US5077034A (en) Treatment of tumors with 5-radioiodo-2'-deoxyuridine
Kassis et al. Radiolabeled nucleoside analogs in cancer diagnosis and therapy
US6685913B1 (en) Lipid soluble radioactive metal chelates for tumor therapy
Fairchild et al. Thiouracil distribution in mice carrying transplantable melanoma
Hsieh et al. Rhenium-188-Labeled DTPA: a new radiopharmaceutical for intravascular radiation therapy
Dahle et al. Relative biologic effects of low-dose-rate α-emitting 227Th-rituximab and β-emitting 90Y-tiuexetan-ibritumomab versus external beam X-radiation
Lin et al. Evaluation of three rhenium-188 candidates for intravascular radiation therapy with liquid-filled balloons to prevent restenosis
US20070140961A1 (en) Radiotherapeutic high specific activity tin-117m and methods of use
Yousefnia et al. Preparation and biodistribution assessment of low specific activity 177 Lu-DOTATOC for optimization studies.
Link et al. Targeting disseminated melanoma with radiolabelled methylene blue: Comparative bio-distribution studies in man and animals
US20120251442A1 (en) Methods for Treatment of Tumors by Direct Administration of a Radioisotope
EP1165146A1 (en) Lipid soluble radioactive metal chelates for tumor therapy
Milot et al. Theranostic 64Cu-DOTHA2-PSMA allows low toxicity radioligand therapy in mice prostate cancer model
Chakraborty et al. Evaluation of; 177Lu-EDTMP in Dogs with Spontaneous Tumor Involving Bone: Pharmacokinetics, Dosimetry and Therapeutic Efficacy
US7709613B2 (en) Rhenium-188 and rhenium-186 for treatment of tumors expressing a Na+/I− symporter
Pervez et al. 188 Rhenium-EDTMP: A potential therapeutic bone agent
Chakraborty et al. Potential 166Ho radiopharmaceuticals for intravascular radiation therapy (IVRT)-I:[166Ho] holmium labeled ethylene dicysteine

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): CA JP

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 603723

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2000921373

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000921373

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2366593

Country of ref document: CA

Ref country code: CA

Ref document number: 2366593

Kind code of ref document: A

Format of ref document f/p: F